We are proud to announce that Oxford Immune Algorithmics (OIA), creator of Algocyte, is part of the Creative Destruction Lab-Toronto Health Diagnostics Stream’s 2020/21 graduating cohort, and was one of the top two performers in the CDL-- Atlanta Recovery Stream 2020/2021. The nine-month odyssey that started in Atlanta, U.S. and ended in Toronto, Canada, marks not only a significant milestone for OIA, but one that has positively altered the trajectory of the company.
The OIA team, led by its founders, interacted with leading academics and business leaders in medicine, business and science, who engaged and challenged us through intensive, multiple-to-one and one-on-one sessions. The CDL program works as a marketplace with four checkpoints where high calibre mentors, including former directors of national health institutions, venture capitalists and top academics, vote to save start-ups from elimination, helping them to make it through to the next session.
Around 400 worldwide start-ups, ready to help the world recover from the pandemic, applied to join the CDL Recovery stream in 2020. Twenty were selected and only two graduated, one of which was OIA. We are honoured to be acknowledged and chosen by such a distinguished group of world leaders.
With the help of CDL and its mentors, OIA has reached several new milestones, including establishing a biochemical lab in Atlanta, in partnership with Georgia Tech, to advance our microfluidics technology; fundraising and closing a £5.1M seed round led by Medtech AI; and welcoming Pam Winsor, former CMO of Medtronic Canada, who joined OIA's board as Chair.
The Creative Destruction Lab is a seed-stage accelerator that began in 2012 at the University of Toronto’s Rotman School of Management and currently runs ten accelerators in the U.S, Europe and Canada. In addition, it is an engine for scaling and funding deep tech companies, supporting CDL’s “innovative mindset,” and one of its key focus areas is computational health. The not-for-profit is funded by the Canadian government’s Strategic Innovation Fund and includes accelerators from future and space tech, artificial intelligence, blockchain, smart cities, health and quantum computing.
Oxford Immune Algorithmics (OIA) is an award-winning Deep MedTech company incubated by the University of Oxford with a mission to rid the world of preventable diseases. It operates multi-nationally to build technology that moves healthcare away from its reliance on population-wide symptom pattern matching toward value-based precision medicine and personalised diagnostics.
OIA, key partner in UK’s EPSRC research network, awarded grant to explore the future of blood testing
Oxford Immune Algorithmics' (OIA) continues to be acknowledged both internationally and in the U.K. The recent announcement of the award of an EPSRC Future blood testing for inclusive monitoring and personalised analytics network’ grant cited OIA’s role as a key partner, “essential in an interdisciplinary remote blood-testing monitoring network”. The EPSRC is the funding arm for Engineering and Physical Scientific research in the U.K.
The project funded by the grant, spearheaded by Dr. Weizi Li, Deputy Director of the Informatics Research Centre at the Henley Business School, University of Reading, aims to explore solutions that will enable patients and health professionals to carry out their blood tests remotely, greatly accelerating decision-making, the processing of blood samples, and the delivery of diagnoses, all of which have been made more urgent than ever by Covid-19.
Clinical healthcare continues to face challenges in obtaining and processing blood samples outside of clinical platforms, and reducing labour-intensive and manual tweaking, which are not suited for home blood monitoring. All of these factors significantly hamper the timely analysis of blood samples. Capturing patients' sequential data over time to compile information crucial to the early detection of complex diseases has been identified as the only way to manage chronic health conditions.
In the U.K., more than 500 million biochemistry and 130 haematology tests are conducted annually, with 95% of clinical pathways requiring patients to have access to timely, cost-effective pathology services. Inefficient handling of blood testing and analysis translates into inefficient and late diagnoses of many illnesses, and to opportunities lost due to a lack of knowledge of disease progression and the many attendant health complications.
The interdisciplinary network will look at the entire spectrum of blood testing technologies to “raise awareness, generate big ideas, and highlight blood testing solutions for remote, inclusive, rapid, affordable and personalised blood monitoring”. The network's formation signals a shift in the healthcare industry and acknowledges deficits in the current health system. The network will explore three principal areas: remote monitoring, I.C.T., and personalised data and A.I. to monitor diseases such as cancer, autoimmune diseases, general and pre-operative care.
The EPSRC aims to maintain the U.K.'s leading position in research and training by providing opportunities for researchers to collaborate. Partners in the network include Stanford University, Cambridge University Hospitals, M.I.T., Karolinska Institute, and the Imperial College London.
Oxford Immune Algorithmics (OIA) is an award-winning Bio and MedTech company incubated by the University of Oxford with a mission to rid the world of preventable diseases. It operates multi-nationally to build technology that moves healthcare away from its reliance on population-wide symptom pattern matching toward value-based precision medicine and personalised diagnostics.
Oxford Immune Algorithmics wins International AI Competition to Predict Etihad's Cash Flow Validating OIA's AI Predictive Algorithms
Oxford Immune Algorithmics (OIA) has been announced the winner of Etihad’s AI international competition. Etihad Group Finance, owner of award-winning Abu Dhabi-based Etihad Airlines, held the competition with partners such as HUB71 and Accenture (Fortune Global 500) that also attracted other major, international competitors from around the world. OIA competed against these companies, Etihad’s own data analytics department and Accenture itself.
This new accolade demonstrates how the AI algorithms developed by OIA to solve problems in genetics and molecular biology as published in top academic journals can be translated to an industry challenge for time series prediction in a completely different context.
OIA’s excellent technical ability in reviewing the raw data and ability to derive business insights clearly helped Oxford Immune Algorithmics develop a more accurate model than other competition participants, who took more generic ML modelling approaches”
This new achievement provides further validation of OIA’s causal predictive algorithms used in their flagship product Algocyte for precision medicine and health diagnosis. The algorithms required little adaptation to this problem and outperformed all other competitors. OIA will be awarded $10,000 USD and has been invited to implement the forecasting platform for Etihad's Aviation Group at a global scale.
The competition spearheads OIA’s delivery of world class AI to an international airline brand that will enhance its predictive financial forecasting with OIA’s algorithms. The announcement highlights the leading position of the company and their founders, former researchers of the University of Oxford spearheading AI for causal prediction.”
The competition’s objective was to enable a Machine Learning solution that would leverage an integrated repository of financial & operational data across three areas; time horizon, accuracy, and level of detail. The goal was to predict Etihad's unpublished data with an accuracy equal to or greater than 90% compared to actual time series data taking into account previous history, to assist in managing the company's liquidity with minimal intervention. The competitors were free to select internal or external variables and come up with a comprehensive adaptable model.
The proposed solution specified the use of advanced analytics to inform predictive cash flow forecasting, automation to enable semi-automated construction of cash position & projection of future cash flows. Oxford Immune Algorithmics delivered the winning solution.
Oxford Immune Algorithmics (OIA) is an award-winning Bio and MedTech company incubated by the University of Oxford with a mission to rid the world of preventable diseases. It operates multi-nationally to build technology that moves healthcare away from its reliance on population-wide symptom pattern matching and toward value-based precision medicine and personalised diagnostics.
OIA’s flagship AI Medical Assistant, Algocyte, will be integrated into MyGlobalHome’s digital health ecosystem, allowing users to complete personal blood tests remotely at will, and access the results from home via a smart monitor.
At MyGlobalHome, our vision for the future is that homes will look after their occupants – not the other way round. The integration of Algocyte is a vital step towards realising this vision, and we are absolutely delighted to be partnering with Oxford Immune Algorithmics on this project.”
BDaily covered the news
Drawing on more than a decade of research in computational biology and systems medicine conducted at institutions such as the the University of Oxford, and the Karolinska Institute, and on their experience in industry, Dr. Hector Zenil and Dr. Jürgen Riedel set out to develop Algocyte with the help of an exceptional team that believed in the company's mission and could support it over the years. Most of the original team stuck around, and has witnessed a series of successful events including this last fundraising round involving a great team of investors fully aligned with the founders' vision.
Algocyte is a platform for remote health monitoring and pre-diagnosis based on model-driven AI able to tell apart cause from effect with features that range from patient triaging using smart adaptive risk assessment scores to providing robust predictions based on perturbation analysis by learning from the user's own health behaviour over time. Algocyte delivers on the promise of precision medicine and has the potential to help transform healthcare from cost-effective to value-based patient-centric care freeing clinicians to devote more quality time to patients, who themselves will be able to participate more actively in their own care.
The funding round was led by Toronto-based Medtech AI Ltd, a group of high-profile North American investors based in Canada and the U.S. specialising in medical devices, finance, and energy, but also including high-profile investors in software area.
Already in a position to demonstrate the technology, we are confident that cost-effective and radically new ways brought by OIA will open up huge growth opportunities for medicine and healthcare around the world.”
SFC Capital, which invested in OIA last year, joined this new round with a follow-up showing great confidence in the company's team, vision and progress during the last year despite the pandemic.
In a world devastated by the recent pandemic, the need for remote immune monitoring systems is more apparent. The team at OIA has the credentials, industry experience and skills set to drive this transformation forward. We have been involved in the company for the past year and since our initial investment we have been very much impressed by the development to date and are looking forward to OIA transforming medicine and changing healthcare”
Joining the company as the board Chairwoman is Pamela Winsor, who was OIA's mentor at the prestigious and highly-competitive Creative Destruction Lab, an accelerating programme based in its U.S. American branch. OIA was one of only 20 stat-up applications selected out of a total of 400, and one of only 3 remaining by the end of the Recovery programme held in Atlanta U.S., a programme designed by CDL to support start-ups helping the world bounce back from the pandemic.
Pamela is the former CMO of Medtronic Canada. Medtronic is the largest medical devices company in the world. Pam brings a lot of credibility to OIA's mission and more than 25 years of experience as a visionary in value-based healthcare and precision medicine.
The future of healthcare is here and we are excited to be partnering with the outstanding Oxford Immune Algorithmics (OIA) team to ensure that this 'at home' AI driven, value-based diagnostic solution is well positioned and accessible to all. Personalized and precision medicine is here!”
The funds will be used to continue R&D, establish a low-volume production facility, generate robust data for regulatory purposes, increase protectable IP, accelerate compliance and expand the team this year from its current 20 part-time to around 30 full-time top talent employees in order to achieve OIA's ambitious goals, while bringing current team members currently spread all over the world to work out of OIA's offices in the U.K. and the U.A.E. For this, OIA has contracted Vivid Technologies as its recruitment arm.
Medtech is also planning to follow up in future rounds, as needed, to help OIA raise the funds to go to market in the U.K., Europe, Canada, the U.S., and globally.
THE AGENDA ON FEBRUARY 23 2021
TIME (UAE ) PROGRAM
5:00 pm - 5:10 pm Get together & Warm-up
5:10 pm - 5:15 pm Welcome address
5:15 pm - 5:25 pm Speech by Dr Assem Al-Hajj
5:25 pm - 5:35 pm Speech by Dr Hector Zenil
5:35 pm - 5:45 pm Signing Ceremony
5:45 pm - 5:55 pm Closing Remarks & Virtual Group Photo
Oxford Immune Algorithmics (OIA) is honoured to announce a new partnership with a major university in the UAE, Khawarizmi International College or KIC, made possible by Dr Assem Al-Hajj, KIC President, Prof. Nabil El Kadhi, Vice President of Academic Affairs, Dr. Hector Zenil, OIA CEO, and Dr. Lionel Khalil, Head of Legal and International Development at OIA.
His excellency, Mr Patrick Moody, UK Ambassador, and several other high-level officers from the local UAE and Abu Dhabi government and the UK embassy, including Pippa Russo, Life Sciences Advisor at the Department for International Trade at the British Embassy in Abu Dhabi, and the Trade Commissioner and Consul-General in Dubai, Mr Simon Penney, confirmed their presence at the virtual ceremony.
OIA's co-founders, Dr. Hector Zenil and Dr. Jürgen Riedel, together with a dozen of other OIA's staff members, attended the ceremony with a total of about 40 attendants including local authorities, heads of department and other KIC staff. OIA founder, Dr. Hector Zenil, made a presentation outlining OIA's future goals, and highlighted how the the two organisations will collaborate. KIC President, Dr. Assem Al Kajj, presented the goals of Khawarizimi and their excitement for working together with OIA.
Founded in 1985, Khawarizmi International College (KIC) is one of the first private higher education institutions in the UAE to be accredited by the Ministry of Education, offering Bachelor and Diploma degrees in Business Administration, IT and Computer Graphic Design, Health and Medical Sciences, and Mass Communication. Over the course of 35 years, the university has graduated more than 11,000 alumni empowered by engaging applied educational experiences to meet the needs of the industry and the community.
It is clear that KIC and OIA are the perfect partners. For those that are not familiar with the story behind our flagship product name Algocyte, the first part of the name comes from Algorithm, which is the latinisation of Al Khawarizmi, the polymath who advanced the field of algorithms, and is also in the name of KIC. 'Algo' also means pain from the Greek word "álgos". And "cyte" in Algocyte is derived from the Greek word "kytos” meaning container or cell.
Two of the main areas taught at KIC are computer sciences, and health and medical sciences, the very topics of interest in our own company. We look forward to a fruitful relationship that will complement both organisations.
Event photo with agreements signed
One major project that OIA wants to achieve with KIC as a partner is to prove OIA's technology in space, making it possible for Emirati astronauts to be closely monitored and screened for any health conditions bringing us closer to Star Trek's medical tricorder technology. OIA's aim is to have a prototype working at the Mars City near Dubai to help astronauts train using cutting-edge medical technology and then in real space.
U.A.E.'s Mars City Dubai
The KIC announcement can also be read here.
Co-founder and CTO, Dr. Jürgen Riedel, is interviewed by Founderella
The startup Oxford Immune Algorithmics belongs to the current class of the Leipzig SpinLab. With the help of artificial intelligence, it wants to detect diseases faster. "
Read the full interview here
SpinLab, one of the best-ranked accelerating programmes in Europe based in Leipzig, Germany, has selected a handful of startups out of hundreds of applications, including OIA, to be supported and introduced to SpinLab's partners in the areas of application relevant to OIA's flagship product, Algocyte, including insurance companies and healthcare organisations.
SpinLab is a partner of the HHL Leipzig Graduate School of Management, one of Europe's most prestigious business schools, and works with a partner portfolio of over 25 corporations. This will open up OIA's network in Europe.
Supported by HUB71, a new subsidiary of OIA, Immune Algorithmics Middle East Ltd, has officially started operations and opened an office in Abu Dhabi. Soon, the first team will be landing in the new office seeking to raise funds and start commercial agreements in the region. OIA is planning to use its Middle East office to expand to the Middle and Far East.
Abu Dhabi and the United Arab Emirates are an international hub, technology magnet and an unmatched location for business in the region. The new office is located in the 16th floor of a building in a prime location at the Abu Dhabi Global Market Square (right picture above). The Abu Dhabi Global Market (ADGM) is an international financial centre located on Al Maryah Island in the United Arab Emirates's capital, Abu Dhabi.
OIA has been accepted into the 'CDL-recovery' programme in Atlanta, U.S. with the purpose to explore the U.S. market and contribute to the world recovery during and after COVID-19. Particularly chosen by the Creative Destruction Lab because of our solution's potential to contribute to the challenge of remote health monitoring, OIA and Algocyte are in a privileged position to help medical professionals and patients, specially those with conditions neglected because of the pandemic.
OIA chose Atlanta as its CDL affiliation to explore an incursion into the U.S. and North American markets from a world healthcare hub city. The Creative Destruction Lab (CDL) is a programme for massively scalable, science-based companies that pairs founders with experienced entrepreneurs and investors to set focused, measurable objectives with the goal of maximising equity-value creation. CDL was founded in 2012 in Toronto, Canada by Prof. Ajay Agrawal.
Most global healthcare resources are focused on COVID19 and this is largely disrupting the continuum of care for patients with chronic diseases (Chudasama et al., 2020). It has been reported that fear of contacting GPs during the COVID19 outbreak may be fuelling missed diagnoses (The Guardian, 2020). Results from a poll by NHS England, released in April, revealed that 40% of people said they were avoiding contacting their GP because of concerns about burdening the NHS (GPOnline, 2020).
“During a pandemic, other health conditions do not cease to exist, and we’ve seen from health crises in the past that there are sometimes more deaths from conditions unrelated to the pandemic than the virus causing the pandemic itself”
Many patients with chronic medical conditions or those undergoing diagnostic or therapeutic procedures require regular blood tests. This is currently performed at a hospital, clinic or GP's surgery, or in some cases through a visit by a phlebotomist or a district nurse to the patient’s home. Consequently, the requirement for self-isolation and social distancing during the pandemic has resulted in many patients being unable to receive an optimal level of monitoring. Even in non-pandemic times, the current system of contact-based blood testing is very inefficient and wasteful of precious NHS resources. There is consensus amongst healthcare providers that remote patient consultations could be very effective, and are very desirable, but are hampered by the need for contact-based blood testing (Royal College of Physicians, 2018).
There is also an additional, and more fundamental, problem with how we monitor patient blood results. Blood results are reported based on a binary category of normal or abnormal in comparison with population reference values. However, unsurprisingly, the population ‘normal’ ranges are generally very wide. A crude and simplistic binary categorisation of blood results often implies that even when a patient’s blood values move dramatically within the normal reference values, clinicians can dismiss this change if it remains within the range considered to be healthy. Unquestionably, however, significant rapid changes, for example in total White Blood Cell (WBC) count, are likely to have been precipitated by biologically and potentially medically-consequential causes which are currently ignored. There is now strong evidence that even when all other known factors are taken into consideration, changes in immune cell numbers such as WBC count are predictive of risk of disease and death, even in entirely healthy people (Shah et al., 2017; Alpert et al., 2019). In this context, personalised and longitudinal monitoring of a person’s immune system with a tool like Algocyte®, has the potential to generate important insights into health and disease, particularly in the case of vulnerable patients.
Oxford Immune Algorithmics (OIA) aims to support the health care sector and the NHS with Algocyte®, a service that allows clinicians to remotely monitor their patients' health and immune systems through a Full Blood Count (and possible complementary blood tests).
As part of OIA’s partnership with the NHS, OIA is currently offering service contracts to NHS organisations without charge in order to maximise the patient and societal benefits of this remote blood testing service and help with the increasing demand and accumulated backlog during the pandemic. To this end, we invite organisations to contact us with a description of how immune cell monitoring can help your patients. If appropriate, this service will be subsidised 100% by OIA. Currently, OIA is running pilots at Addenbrooke's Cambridge University Hospitals and the Medici GP Practice (15,000 patients) in Luton.
Millions could be putting their long-term health at risk by not getting the proper monitoring that their conditions need (UniteLive, 2020) and we believe we are in a position to help.
Please contact us by completing the short form at the end of the page:
Sinldo Information Technology Co., Ltd. based in Beijing, is a leading Hospital Information Technology and mobile healthcare solution provider in China. It covers over 1,000 major public hospitals (400+ Grade A/Class A), and 2000 community hospitals and medical institutions, with over 600 million patient visits per year.
Sinldo has connected more than 1.5 million doctors and helps to manage 200 million patients each year. The letter of intent outlines the terms and conditions of a commercial agreement and involves the introduction and commercialisation of Algocyte in the regional hospital network in Shanxi province, An Kang city, Han Bin district, in China where there are 3 hospitals in the city, 36 community hospitals and 400 medical units in the surrounding villages which are connected by Sinldo’s digital platform that covers 1,020,000 people.
Signed by Dr Hongqiao Yang Sinldo, Chairman of Sinldo, the letter also commits to exploring the wider network of Algocyte in hospital networks across China including 3000 regional hospitals and other medical units.
We asked patients and doctors and this is what they said
Patients surveyed about Algocyte found that getting a regular appointment for a blood test was too long (at least a week on average)
which together with the time they had to wait for their blood test results amounted to up to two more weeks in total.
A majority of patients say yes to finger-pricking over the alternatives
Patients find the main features of Algocyte useful.
The number of tests and hours that doctors and nurses request and spend on blood testing is significant
Enabled by the responsible AI-powered capabilities of Algocyte, doctors found that they could save appointments and spend several hours a week on other activities, including providing more time and greater quality of care to patients.
There was a clear consensus on time-saving and usefulness of results and analytics in a remote app and solution for rapid remote blood testing.
* Data collected from a survey independently conducted and answered by 28 people including doctors (all levels), paramedics, nurses, and patients by the Medici Medical Centre clinic in Luton on June 11, 2020, a GP practice with over 15,000 patients.
OIA's CTO Dr. Jürgen Riedel and Senior AI Researcher Dr. Santiago Hernández-Orozco delivered an invited technical talk at the international conference AUTOMATA 2020, the 26th International Workshop on Cellular Automata and Discrete Complex Systems, one of the most reputable conferences in the field.
Jürgen and Santiago explained some of the most fundamental technical aspects behind OIA's A.I. and Machine Learning approaches to transforming medicine from simple statistical pattern-matching to causal diagnostics, and how OIA's methods and technology give it an edge when it comes to robustness (e.g. to perturbations and interventions), generalisation (over-fitting avoidance) and explainability, features of what we call a responsible A.I. approach to applications in healthcare.
According to a survey conducted by London venture capital firm MMC, 40% of European startups that are classified as A.I. companies don't actually use artificial intelligence in a way that is “material” to their businesses. Another percentage are startups or companies that adopt AI, but very few innovate in AI as much as in its domain of application, as OIA with its group of AI leaders and pioneers does.
Here are some of OIA's most recent papers published in some of the top journals in the fields of AI, automata and molecular biology research:
Oxford Immune Algorithmics is sponsoring the 26th International Workshop on Cellular Automata and Discrete Complex Systems AUTOMATA 2020. The conference aims to:
AUTOMATA 2020 will focus on the theory and applications that many of OIA's own proprietary methods are based upon, on the deep connections of discrete dynamical systems complexity theory and algorithmic information. There will be special sessions and tutorials led by OIA's members on Automata in Machine Learning and on Algorithmic Information Dynamics, with a particular emphasis on aspects of computability in causation, AI and reprogrammability. This again shows again OIA's commitment to bridging industry and academia.
We are thrilled to announce that Oxford Immune Algorithmics signed last week a collaboration and commercial agreement with the National Health Service in the UK to serve and continue co-developing Algocyte® in Addenbrooke's Hospital at the Cambridge University Hospitals NHS Foundation Trust, one of the most important hospitals in the UK.
Algocyte® will be deployed at the Department of Paediatric Haematology, Oncology and Palliative Care to help paediatric cancer patients to get supportive monitoring while preventing them to visit the hospital where they are exposed to greater risk of infection due to COVID-19.
We want to thank partners, collaborators and investors that made this possible believing in us and supporting our project to help clinicians and these vulnerable patients.
We are happy to announce that Oxford Immune Algorithmics has been nominated to the OBN awards for the Best Start-up Medtech in the UK. The awards celebrate outstanding achievement throughout the life sciences industry.
OBN is the not-for-profit organisation supporting and bringing together the UK’s life sciences companies, corporate partners and investors. Their 400-plus Member companies are located across the Golden Triangle (Oxford, London and Cambridge) and beyond to Manchester, Nottingham, the Midlands, South Coast and Scotland.
The nomination already feels like winning and we are very grateful to OBN for this prestigious nomination.
OIA has become a sponsor and will join CogX 2020 as an exhibitor with a dedicated virtual booth. CogX is the Festival of AI and Emerging Technology and will take place on the 8th-10th June 2020. CogX has gone
Traditionally held in London, CogX 2020 is going Virtual and has become a pop-up 3-day 36 channel online TV network with a Virtual Expo. They expect to beat their audience target and provide even greater connections to everyone involved. I hope you find you at our virtual booth at CogX 2020!
OXFORD IMMUNE ALGORITHMICS IS AWARDED A GRANT TO EXPLORE Applications of automata to areas of causation and machine intelligence
OIA has been awarded a grant by recommendation of the Foundational Questions Institute & Fetzer Franklin Fund, a donor advised fund of the Silicon Valley Community Foundation.
The FQXi catalyses, supports, and disseminates research on questions at the foundations of physics, particularly new frontiers and innovative ideas integral to a deep understanding of reality.
The mission of the Fetzer Franklin Fund is to explore the frontiers of scientific knowledge and to advance breakthroughs towards scientific views of reality that are integrated and relational. the Fetzer Franklin Fund focuses on foundational questions at the frontiers of physics, biology, and consciousness research. The Fund supports work that re-examines the foundations of science, including scientific methodologies for both conventional and frontier research.
The Silicon Valley Community Foundation is the largest regional grant maker in the United States and was conceived to advance innovative philanthropic solutions to challenging problems, engaging donors to make the world a better place for all and
Our CEO, Dr. Hector Zenil, will be delivering the opening Keynote at the Predictive Analytics World summit on May 11, 2020 originally planned to be held in Munich, Germany but now to be held online. He will be talking about Responsible AI in Health Care and Medicine, our research at the forefront of science at OIA and our approach with Algocyte®. Other speakers include Dr. Anna Bauer-Mehren, Head of Data Science at Roche; and Dr. Joran Lookerbol, Director of the Centre for Machine Learning at the Netherlands Institute of Mental Health.
We are sponsors, again, of the Intelligent Health summit where Dr. Kourosh Saeb-Parsy, OIA's Chief Medical Officer, will make a major announcement introducing Project Lancelot, OIA and Algocyte's response to Covid-19 (or its consequences) with our remote health monitoring cutting-edge technology for which OIA was created and we now finds itself in the middle of a pandemic being able to make an important contribution to the challenges posed by the crisis.
Pictures from the previous Intelligent Health summit earlier in 2020 at the ExCel conference centre in London (today, unfortunately, converted into the Nightingale's Hospital because of Covid-19, almost overnight becoming one of the largest hospitals in the world)
We have successfully closed our latest funding round with SFC and KIN Capital leading it, award winning investors, both joining last week our multinational shareholder's board supporting OIA.
This is a major milestone as other startups and companies find it increasingly difficult to find funding in a time of crisis. We are very proud to have SFC and KIN joining OIA's journey and for the trust placed on us by investors of this calibre, it feels very much like validation of what we have been doing in the last 1.5 years developing Algocyte®.
We are thrilled that SFC and KIN have seen value in OIA even (or especially) in times like a pandemic. Their investment will help us respond to the increasing interest we are seeing in our services from the NHS. We will now start our next funding round and it is already looking very promising as we are in advanced talks with some of the largest and greatest VCs in the UK.
According to the organisers, STHLM TECH is the largest startup event in Europe where every geek, hacker, entrepreneur, investor, and designer around Stockholm comes together under one roof.
In this edition, there were 3 special guests announced, including leading investors from Canada and Holland. Omers is behind many of the top startups from Canada including Shopify, and DuckDuckGo. Originally planned to be held at the Hilton Slussen in Stockholm, the event was streamed live from live.sthlmtech.com on Monday 6 April, 2020.
Representing OIA was Dr. Kourosh Saeb-Parsy, our Chief Medical Officer, who gave a great pitch about Algocyte® for which we received useful feedback from investors and organisers who were very optimistic about our approach and business model.
There were around 140 attendants and more than 50 of them voted for the best company pitch:
OIA's Algocyte® pitch won by a large percentage (82%) against two other great startups, and we got very useful feedback from top investors.
Oxford Immune Algorithmics (OIA), like almost every other company and organisation around the world is putting in place contingency plans to downsize operations and send people home to work remotely while trying to be the least disruptive in the development and evolution of our products and goals.
We believe that the current situation is a challenge but also an opportunity. We believe that the current crisis will help humanity better rank priorities, realise that these events can happen and may become the norm if this new family of virus becomes seasonal with different degrees of disruption. We can acknowledge how unprepared was the world to face this challenge and how important would have been to have the means to monitor people's health remotely. Indeed, during a crisis like this one patients are asked to avoid coming to hospitals and surgeries even if they are seriously ill yet unable to get care because of risk of infection. This doesn't have to happen with Algocyte®.
OIA has been working on Algocyte® for almost 2 years and has now a full end-to-end CE Marked (under the CE Medical Device directive) app for remote blood testing and health monitoring that can help with these situations and may even save lives by enabling medical doctors to provide coverage without risk of infection for the health professional or the patient.
We are certain that OIA and Algocyte® will become thus even more relevant because we had our priorities right and we knew this was something the world requires to better handle medical emergencies and, in general, regular patient monitoring.
If our vision resonates with your and you believe that we can make a difference as a health or medical professional to your organisation or practice please contact us at email@example.com